Comparative humoral response of mRNA and inactivated vaccines against COVID-19 in healthy adults aged 60 years and older

Meryem Güvenir; Özel Yürüker; Osman Yetkin; Kaya Süer; Barış Otlu

doi:10.3855/jidc.16842

Comparative humoral response of mRNA and inactivated vaccines against COVID-19 in healthy adults aged 60 years and older

Authors

Meryem Güvenir Cyprus Health and Social Sciences University, Faculty of Medicine, Department of Medical Microbiology, Güzelyurt, Cyprus https://orcid.org/0000-0002-9702-9947
Özel Yürüker Cyprus Health and Social Sciences University, Faculty of Medicine, Department of Immunology, Güzelyurt, Cyprus
Osman Yetkin Near East University, Faculty of Medicine, Department of Biochemistry, Nicosia, Cyprus
Kaya Süer Near East University, Faculty of Medicine, Department of Infectious Diseases and Clinical Microbiology, Nicosia, Cyprus
Barış Otlu İnönü University, Faculty of Medicine, Department of Medical Microbiology, Malatya, Turkey

DOI:

https://doi.org/10.3855/jidc.16842

Keywords:

COVID-19, vaccine, humoral immunity, cellular immunity, Cyprus

Abstract

Introduction: A vaccine against coronavirus disease 2019 (COVID-19) is critically needed for older adults because of the increased morbidity and mortality rates.

Methodology: In this prospective study, we analysed the titre magnitude of the IgG antibodies directed against the SARS-CoV-2 Spike Protein S1 (S1-RBD) antigen in both CoronaVac and Pfizer-BioNTech groups. The samples were tested to detect antibodies that bind to the receptor-binding domain of the spike protein of SARS-CoV-2 using the Enzyme-Linked Immunosorbent Assay (ELISA) technique with SARS-CoV-2 IgG II Quant. The cut-off value was > 50 AU/mL. GraphPad Prism software was used. Statistical significance was defined at p < 0.05.

Results: The CoronaVac group (12 females, 13 males) had a mean age of 69.64 ± 1.38 years. The Pfizer-BioNTech group (13 males, 12 females) had a mean age of 72.36 ± 1.44 years. The anti- S1-RBD titre decrease rate from the 1^st to the 3^rd month for CoronaVac and Pfizer-BioNTech groups was 74.31% and 86.48%, respectively. There was no statistically significant difference in the antibody titre between the 1^st month and 3^rd month for the CoronaVac group. However, there was a significant difference between the 1^st and 3^rd month in the Pfizer-BioNTech group. In addition, there was no statistically significant difference in the genders between the 1^st and 3^rd month of the antibody titres for both the CoronaVac Pfizer-BioNTech group.

Conclusions: The levels of anti-S1-RBD, the preliminary outcome data of our study, represents one piece of the puzzle of humoral response and duration of vaccination protection.

Downloads

Published

2023-02-28

How to Cite

Güvenir M, Yürüker Özel, Yetkin O, Süer K, Otlu B (2023) Comparative humoral response of mRNA and inactivated vaccines against COVID-19 in healthy adults aged 60 years and older. J Infect Dev Ctries 17:178–181. doi: 10.3855/jidc.16842

Download Citation

Endnote/Zotero/Mendeley (RIS)

Issue

Vol. 17 No. 02: February 2023

Section

Coronavirus Pandemic

License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors who publish with this journal agree to the following terms:

Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).